Clinical Trials

NCT Number: NCT04420702 Phase: Not Applicable Trial Summary: Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically si – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Washington University School of Medicine Acronym:

NCT Number: NCT04815876 Phase: NA Trial Summary: Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistanc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: PREVENT2

NCT Number: NCT04984343 Phase: Phase 2 Trial Summary: The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with lo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: FORT

NCT Number: NCT05424783 Phase: Not Applicable Trial Summary: The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Northwestern University Acronym: MAGIC

NCT Number: NCT05668351 Phase: NA Trial Summary: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medical University of South […]

NCT Number: NCT04396808 Phase: Not Applicable Trial Summary: This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC cl – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

NCT Number: NCT05489211 Phase: Phase 2 Trial Summary: TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): AstraZeneca Acronym:

NCT Number: NCT05558956 Phase: Early Phase 1 Trial Summary: Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning pro – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): BAMF Health Acronym:

NCT Number: NCT05932862 Phase: PHASE1 Trial Summary: This is a first-in-human, multicenter, open-label Phase I study. The study will be comprised of a dose escalation part followed by a dose selection optimization part. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Exelixis Acronym:

NCT Number: NCT05617040 Phase: Phase 1|Phase 2 Trial Summary: This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for pros – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Barinthus Biotherapeutics Acronym: